EDSA
Edesa Biotech·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About EDSA
Edesa Biotech, Inc.
A clinical-stage biopharmaceutical company that developing drugs for dermatological and anorectal diseases
Biological Technology
09/09/1999
11/05/2015
NASDAQ Stock Exchange
17
09-30
Common stock
100 Spy Court, Markham, ON, Canada L3R 5H6
--
Founded on September 9, 1999, Edesa Biotech, Inc., is a biopharmaceutical company that develops innovative therapies for inflammation and immune-related diseases, with a clinical focus on medical dermatology and respiratory diseases. Its dermatology product line includes EB06, an anti-CXCL10 monoclonal antibody under development for vitiligo, a Phase 2 study approved by Health Canada and in discussions with the U.S. FDA, and EB01 (1.0% daniluromer cream), a Phase 3 ready-to-treat therapy for allergic contact dermatitis. In its respiratory program, EB05 (paridiprubart), a novel stay-oriented therapy, showed statistically significant survival and rehabilitation benefits in a Phase 3 trial of Acute Respiratory Distress Syndrome (ARDS) and continues to be studied under a U.S. government-funded platform. The Canadian government is also supporting development costs through grant funding, and the company is seeking to increase the use of paridiprubart in chronic diseases.
Company Financials
EPS
EDSA has released its 2025 Q4 earnings. EPS was reported at -0.32, versus the expected -0.27, missing expectations. The chart below visualizes how EDSA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
